Why is the BODE index better than FEV1 alone for COPD?

FEV1 predicts COPD mortality with C-statistic 0.65 — only slightly better than chance for discrimination. BODE improves this to C-statistic 0.74, representing a meaningful improvement in prognostic discrimination. More importantly, BODE captures the multisystem nature of COPD: systemic inflammation (BMI loss), functional impairment (6MWD), and perceived limitation (mMRC) — dimensions of disease that FEV1 cannot measure. Two patients with identical FEV1 40% but different BMI, 6MWD, and mMRC have dramatically different prognoses that BODE captures but FEV1 does not.

How does pulmonary rehabilitation affect the BODE index?

Pulmonary rehabilitation (PR) reduces BODE score primarily by improving 6MWD and mMRC, the two exercise/functional components. The BODE improvement study (Cote & Celli, NEJM 2007) demonstrated: PR reduces BODE by approximately 0.5–2 points; each 1-point reduction in BODE is associated with 12% lower all-cause mortality; patients who attend ≥24 sessions of PR show the greatest BODE improvement. BODE reduction by PR represents one of the few proven survival-modifying interventions in COPD, alongside smoking cessation.

What is the BODE index quartile mortality table?

BODE quartile 52-month all-cause mortality (Celli et al., NEJM 2004): Q1 (BODE 0–2) = approximately 19% mortality; Q2 (BODE 3–4) = approximately 32% mortality; Q3 (BODE 5–6) = approximately 40% mortality; Q4 (BODE 7–10) = approximately 80% mortality. These are based on the original validation cohort of 207 COPD patients. The mortality estimates have been replicated in multiple subsequent cohorts with similar results. Note: individual prognosis cannot be precisely predicted — these are population-level estimates.

Can the BODE index be used for hospice eligibility?

BODE provides evidence-based prognostic information relevant to hospice discussions. BODE Q4 (7–10) with approximately 80% 52-month mortality is comparable to or worse than many cancers that qualify for hospice eligibility. Medicare hospice criteria for COPD include: disabling dyspnea at rest on optimal bronchodilator therapy (mMRC 4), FEV1 <30%, cor pulmonale or secondary PH, resting tachycardia >100 bpm, and weight loss >10% in 6 months — all components related to the BODE index. BODE ≥7 supports the prognostic discussion required for hospice referral.

What is the BODE score interpretation table?

BODE Score interpretation: 0–2 = Lowest quartile risk, approximately 19% 52-month mortality, no specific intervention triggered by score alone; 3–4 = Second quartile, approximately 32% mortality, consider pulmonary rehabilitation if not enrolled, discuss trajectory with patient; 5–6 = Third quartile, approximately 40% mortality, referral for lung transplant evaluation appropriate (especially BODE ≥5), intensive PR; 7–10 = Highest quartile, approximately 80% mortality, urgent transplant evaluation if candidate, concurrent palliative care, advance care planning, consider hospice if not a transplant candidate. Track BODE annually to monitor trajectory.

How often should BODE index be measured in COPD?

For stable COPD management: annual BODE calculation is recommended for GOLD Grade 2–4 patients. Semi-annual calculation (every 6 months) for patients with GOLD 3–4 who are approaching BODE ≥5 (lung transplant referral threshold) or have had a recent exacerbation. BODE should be calculated at stable baseline — not during or within 4–6 weeks of an exacerbation. Components that change more frequently (mMRC, 6MWD) can be assessed at every visit; full BODE recalculation is most useful when spirometry is repeated (annually or after therapy change).

Online Medical Tools — BODE Index

Printed on 9/4/2026

For informational purposes only. This is not medical advice.

Pulmonology

BODE Index

The BODE index is a multidimensional COPD prognostic score composed of Body Mass Index (B), airflow Obstruction by FEV1 (O), Dyspnea by mMRC scale (D), and Exercise capacity by 6-minute walk distance (E). Scores range from 0 to 10 and correlate with long-term mortality risk better than FEV1 alone.

Formula: BODE = BMI points (0-1) + FEV1 points (0-3) + mMRC points (0-3) + 6MWD points (0-3), total 0-10.

BMI

kg/m^2

FEV1 (% predicted)

mMRC Dyspnea Grade

6-minute walk distance

meters

Save your results with a free account

Keep a history of calculations, favorite tools, and access your dashboard anytime.

Create free account Sign in

How It Works

Measure and score all 4 BODE components

Score each component from standardized measurements: (1) BMI: >21 kg/m² = 0 points; ≤21 = 1 point. (2) FEV1% predicted (post-bronchodilator): ≥65% = 0; 50–64% = 1; 36–49% = 2; ≤35% = 3 points. (3) mMRC Dyspnea Grade: 0–1 = 0; Grade 2 = 1; Grade 3 = 2; Grade 4 = 3 points. (4) 6-Minute Walk Distance (standardized ATS protocol): ≥350 m = 0; 250–349 m = 1; 150–249 m = 2; ≤149 m = 3 points.

Sum the 4 component scores (total 0–10)

Add all four component scores: BMI (0–1) + FEV1 (0–3) + mMRC (0–3) + 6MWD (0–3) = BODE Index total (0–10). Higher scores indicate worse prognosis.

Interpret the BODE quartile for prognosis and referral decisions

52-month all-cause mortality by BODE quartile: Q1 (BODE 0–2) ≈ 19%; Q2 (3–4) ≈ 32%; Q3 (5–6) ≈ 40%; Q4 (7–10) ≈ 80%. BODE ≥5 or BODE 3–4 with rapid progression triggers lung transplant referral evaluation per ISHLT 2023 guidelines. Serial BODE (annually or semi-annually) tracks disease trajectory — each 1-point reduction in BODE after pulmonary rehabilitation is associated with 12% reduced all-cause mortality.

Who Uses the BODE Index

COPD Mortality Risk Communication

Pulmonologists & Palliative Care Teams

The BODE index provides a validated, nuanced mortality prediction that surpasses FEV1 alone (C-statistic 0.74 vs 0.65). BODE quartile 4 (score 7–10) carries approximately 80% 52-month all-cause mortality — comparable to many advanced malignancies. This information enables evidence-based advance care planning discussions, goals-of-care conversations, and appropriate referral to palliative care for patients with end-stage COPD.

Lung Transplant Referral Threshold (BODE ≥5)

Transplant Pulmonology Teams

ISHLT 2023 lung transplant listing guidelines include BODE ≥5 as a referral indication. BODE 3–4 with rapid FEV1 decline (>100 mL/year), PaCO₂ >50 mmHg, or secondary pulmonary hypertension also warrant referral discussion. BODE provides a multidimensional risk estimate that helps justify transplant evaluation timing — patients with BODE ≥7–8 have very limited expected survival without transplantation and should be prioritized.

Pulmonary Rehabilitation Outcome Tracking (Serial BODE)

Respiratory Therapists & Pulmonary Rehab Teams

BODE reduction is one of the primary outcome metrics for pulmonary rehabilitation efficacy in COPD. Cote & Celli (NEJM 2007 — BODE improvement study) demonstrated that each 1-point decrease in BODE after PR is associated with 12% reduced all-cause mortality. A significant BODE improvement (>1 point) indicates exercise capacity and dyspnea gains that translate to real-world survival benefit. Pre- and post-PR BODE comparison is standard in pulmonary rehab program quality measurement.

Lung Volume Reduction Surgery (LVRS) Candidate Selection

Thoracic Surgery Teams

LVRS is appropriate for select patients with upper-lobe predominant emphysema and low exercise capacity. The NETT trial identified that patients with upper-lobe predominant emphysema and low 6MWT (<25W on cycle ergometer) benefit most from LVRS, improving BODE index. BODE provides a pre-operative prognosis estimate and helps select patients likely to benefit from the surgery's risk. Post-LVRS BODE improvement confirms surgical benefit.

Advanced Care Planning in Severe COPD

Palliative Care & Geriatrics Teams

BODE 7–10 (80% 52-month mortality) provides an objective basis for discussing prognosis with patients and families in a way that FEV1 alone does not convey. This enables informed goals-of-care discussions: mechanical ventilation preferences, hospice eligibility planning, oxygen therapy goals, and advance directive completion. Patients with BODE ≥7 and repeated exacerbations may benefit from concurrent palliative care referral while pursuing active COPD management.

Pro Tips

BODE captures multisystem COPD impact that FEV1 misses

FEV1 alone has a C-statistic of 0.65 for all-cause mortality prediction in COPD — only modestly better than chance. BODE improves this to 0.74 by incorporating nutritional status (BMI), functional breathlessness (mMRC), and exercise capacity (6MWT). In a patient with GOLD 3 (FEV1 40%) and BODE 3 (good 6MWT, low dyspnea, normal BMI), prognosis is substantially better than another GOLD 3 patient with BODE 8 (low 6MWT, severe dyspnea, low BMI). BODE personalizes risk communication beyond spirometry.

6-minute walk test must follow ATS standardized protocol

BODE validation used the ATS 2002 6MWT protocol: 30m flat indoor corridor, standardized encouragement phrases, no warm-up exercise before the test, minimum 30 minutes rest from oxygen tank change or exercise, record O₂ use and SpO₂. Deviations from this protocol make 6MWD incomparable to the BODE validation cohort. Common errors: conducting 6MWT in short hallways requiring frequent turns, allowing treadmill or track surface, or providing non-standardized verbal encouragement.

BODE ≥5 triggers lung transplant referral evaluation

ISHLT 2023 transplant guidelines include BODE ≥5 as one criterion for referral for lung transplant evaluation in COPD. Referral at BODE 5 allows adequate time for pre-transplant workup (cardiac evaluation, psychosocial assessment, nutritional optimization), patient education, and listing — since 6–18 months may elapse between referral and listing, and longer waits occur at some centers. Do not wait for BODE ≥7–8 to initiate referral discussion, as by that point the patient may be too ill to survive transplant.

Low BMI in COPD signals cachexia and worsens prognosis

BMI ≤21 kg/m² (1 BODE point) in COPD indicates pulmonary cachexia — a loss of fat-free mass driven by systemic inflammation, increased energy expenditure, and inadequate caloric intake. Pulmonary cachexia is an independent mortality predictor in COPD. Nutritional intervention: high-calorie, protein-rich diet (30–35 kcal/kg/day, protein 1.2–1.5 g/kg/day), oral nutritional supplements, and resistance training (pulmonary rehabilitation). BMI improvement can reduce BODE score and improve prognosis.

Pulmonary rehabilitation reduces BODE by 1–2 points

The BODE improvement study (Cote & Celli, NEJM 2007) in 744 COPD patients demonstrated that PR reduces BODE by an average of 0.5–2 points. Crucially, each 1-point BODE reduction was associated with 12% lower all-cause mortality, independent of baseline BODE. This is one of the few interventions in COPD (alongside smoking cessation) shown to reduce mortality risk. PR achieves BODE reduction by improving 6MWD (exercise training component) and mMRC (better fitness reduces perceived dyspnea).

Use post-bronchodilator FEV1 for BODE calculation

The FEV1 component of BODE requires post-bronchodilator FEV1% predicted — consistent with GOLD staging. Pre-bronchodilator FEV1 may underestimate true FEV1 and overestimate the BODE score by 0–1 points, misclassifying patients into higher-risk quartiles. Always use the most recent post-bronchodilator spirometry values for BODE calculation. If only pre-bronchodilator values are available, document this limitation in the clinical note.

BODE should be performed at stable baseline, not during exacerbation

Like mMRC, 6MWT should not be performed during or within 4–6 weeks of an acute COPD exacerbation, as exercise capacity and dyspnea are transiently worse during and after exacerbations. BODE calculated during or immediately after an exacerbation will overestimate BODE score and may erroneously escalate clinical decision-making (inappropriate early transplant referral). Document the date and that assessment was performed at stable baseline.

Monitor BODE annually in GOLD 3–4 patients

Annual BODE calculation in patients with GOLD Grade 3–4 COPD allows detection of trajectory changes that should prompt management escalation. A BODE increase of >1 point per year suggests rapid progression warranting: (1) Review of pharmacologic therapy; (2) Referral for pulmonary rehabilitation; (3) Lung transplant evaluation discussion (BODE ≥5); (4) Assessment for surgically correctable emphysema (LVRS candidacy); (5) Consideration of concurrent palliative care for BODE ≥7.

BODE improvement after LVRS in select upper-lobe patients

The NETT trial (NETT Research Group, NEJM 2003) demonstrated that LVRS improves BODE score in patients with upper-lobe predominant emphysema and low baseline exercise capacity — but not in those with lower-lobe disease or high exercise capacity. Post-LVRS BODE improvement reflects improvement in both 6MWT (better V/Q matching after excising hyperinflated bullae reduces dead-space ventilation) and mMRC (reduced hyperinflation improves diaphragm mechanics). Surgical mortality risk must be weighed against BODE-predicted survival benefit.

Declining BODE >1 point per year signals accelerating disease

In patients followed longitudinally, a BODE increase >1 point over 12 months — particularly if driven by 6MWD decline — signals accelerating disease progression that may not be captured by FEV1 trajectory alone. Investigate underlying causes: new cardiovascular comorbidity, deconditioning from a recent exacerbation, anemia, heart failure, or OSA. This rate of decline supports urgent lung transplant evaluation discussion and escalation of all COPD management strategies.

Common Questions About Your Results

Non-standard 6MWT conditions (short corridor with multiple turns, outdoor use, treadmill, non-standardized encouragement, inadequate rest beforehand) can produce 6MWD values that are 10–20% different from those obtained with the standard protocol, potentially shifting a patient between BODE point categories. For formal BODE calculation and documentation (e.g., lung transplant evaluation), re-do the 6MWT with ATS 2002 protocol: 30m minimum flat indoor corridor, rest ≥10 minutes before test, standardized verbal encouragement every minute, and measure at end of 6 minutes. Small hallways are the most common practical barrier — a 20m corridor requires more turns and reduces 6MWD.

BODE ≥5 is an indication to initiate the referral conversation and evaluation process — not necessarily to list the patient urgently. At BODE 5, the patient has approximately 40% 52-month mortality and time is available for comprehensive pre-transplant evaluation. Discuss with the patient: goals and values regarding aggressive intervention, transplant process and recovery expectations, smoking cessation requirement (typically 6 months before listing), and optimize all medical management before listing. Early referral (at BODE 5) is preferred over late referral (BODE 8+) because the patient is still fit enough to withstand the procedure.

Pre-bronchodilator FEV1 is typically 10–15% lower than post-bronchodilator FEV1 in COPD patients with reversibility. Using pre-bronchodilator values may add 0–1 point to the FEV1 BODE component, potentially shifting the patient from BODE Q2 (3–4) to Q3 (5–6) or Q3 to Q4 — significantly affecting prognostic communication and transplant referral timing. For BODE calculation, always use post-bronchodilator spirometry. Document 'pre-BD FEV1 used' if post-BD values are unavailable, and note the limitation in the clinical record.

An mMRC assessed during acute exacerbation may be 1–2 grades higher than the stable baseline mMRC, adding 1–2 BODE points and potentially causing significant BODE overestimation. Wait 4–6 weeks after full clinical recovery before calculating BODE for clinical decision-making purposes (especially for lung transplant referral or goals-of-care discussions). Use the most recent stable-baseline mMRC from the clinic records for BODE calculation if the patient is currently exacerbating.

Evidence-Based Methodology

BODE Index by Celli et al. (NEJM 2004) from 207 COPD patients; C-statistic 0.74 vs 0.65 for FEV1 alone for all-cause mortality. BODE 7–10 group: 80% 52-month mortality. Pulmonary rehabilitation improves BODE: Cote & Celli (NEJM 2007) — each 1-point decrease = 12% mortality reduction. ISHLT 2023 lung transplant listing guidelines include BODE ≥5. BODE after LVRS: NETT Research Group (NEJM 2003). 6MWT standardization: ATS Statement (Am J Respir Crit Care Med 2002).

Clinical Content Trust

Last reviewed:: April 21, 2026
Guideline version:: General evidence framework v2026.04
Source set version:: Primary-source set v1

How to Interpret Your Result

Higher BODE scores suggest progressively higher mortality risk and greater COPD severity burden.

When to Use This Tool

Use BODE during comprehensive COPD follow-up when spirometry, dyspnea grade, BMI, and 6-minute walk results are available.

Limitations

BODE is prognostic and cohort-derived; it does not capture all comorbidities or short-term exacerbation dynamics and should complement, not replace, clinical judgment.

For related assessments, see COPD GOLD, mMRC Dyspnea Scale and Pack-Year Calculator.

Disclaimer: This tool is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about your health.

Changelog

April 21, 2026 · trust-baseline
Clinical trust metadata enabled for this tool page with structured review/version fields.

Related Tools

Pulmonology

COPD GOLD

Classify COPD severity using 2024 GOLD spirometric stages (GOLD 1–4) and ABE exacerbation grouping. Guides inhaler step-up therapy, pulmonary rehabilitation, and oxygen therapy decisions.

Open Pulmonology

mMRC Dyspnea Scale

Grade baseline breathlessness from 0 to 4 with the modified Medical Research Council (mMRC) dyspnea scale.

Open Pulmonology

Pack-Year Calculator

Calculate pack-years from cigarettes per day and years smoked. Useful for documenting smoking burden and lung cancer screening discussions.

Open Pulmonology

ACT Score

Calculate the Asthma Control Test score to assess asthma control over the past 4 weeks.

Open

Frequently Asked Questions

The BODE index is a multidimensional COPD prognostic score created by Celli et al. (NEJM 2004) that predicts all-cause mortality better than FEV1 alone. BODE stands for: B = Body mass index (BMI ≤21 = 1 point, >21 = 0); O = airflow Obstruction by FEV1% predicted (0–3 points); D = Dyspnea by mMRC grade (0–3 points); E = Exercise capacity by 6-minute walk distance (0–3 points). Total score 0–10 predicts 52-month all-cause mortality from ~19% (score 0–2) to ~80% (score 7–10).

Sum the 4 component scores: BMI: >21 kg/m² = 0 points; ≤21 = 1 point. FEV1% predicted: ≥65% = 0; 50–64% = 1; 36–49% = 2; ≤35% = 3. mMRC Dyspnea Grade: Grade 0–1 = 0; Grade 2 = 1; Grade 3 = 2; Grade 4 = 3. 6-Minute Walk Distance: ≥350m = 0; 250–349m = 1; 150–249m = 2; ≤149m = 3. Total BODE = 0–10. Example: patient with BMI 22 (0), FEV1 45% (2), mMRC 2 (1), 6MWD 280m (1) = BODE 4.

A BODE score of 7 falls in BODE Quartile 4 (score 7–10), which is associated with approximately 80% 52-month all-cause mortality — meaning about 80% of COPD patients with this score die within 4.3 years. This is comparable to the prognosis of many advanced malignancies. BODE 7 is a strong indication for: urgent lung transplant evaluation, comprehensive palliative care integration alongside active management, goals-of-care and advance directive discussions, and hospice consideration if the patient is not a transplant candidate.

The four BODE components and their scoring: (1) BMI (Body mass index): captures nutritional status/cachexia — ≤21 kg/m² = 1 point (bad); >21 = 0 points. (2) FEV1% predicted: captures airflow obstruction severity — 0 (≥65%) to 3 (≤35%) points. (3) mMRC Dyspnea Scale: captures perceived breathlessness — 0 (Grade 0–1) to 3 (Grade 4) points. (4) 6-Minute Walk Distance: captures exercise capacity/physical function — 0 (≥350m) to 3 (≤149m) points. Each component independently predicts mortality; together they provide a comprehensive multidimensional prognosis.

ISHLT 2023 lung transplant listing guidelines include BODE ≥5 as an indication for referral for lung transplant evaluation in COPD. BODE 3–4 with any of the following also warrants referral: FEV1 <25% predicted, PaCO₂ >50 mmHg, rapid FEV1 decline (>100 mL/year), elevated PA pressure, or significant functional decline. Referral (not listing) at BODE 5 is recommended to allow adequate evaluation time. Active BODE monitoring is necessary to identify the optimal transplant window.

The 6-minute walk test (6MWT) measures the maximum distance a patient can walk in 6 minutes on a flat surface, following the ATS 2002 standardized protocol. In COPD, 6MWD reflects integrated cardiopulmonary and musculoskeletal exercise capacity. Normal 6MWD for an adult is 400–700m depending on age, sex, and height. BODE scoring: ≥350m = 0; 250–349m = 1; 150–249m = 2; ≤149m = 3 points. A MCID of approximately 25–35m is recognized for 6MWT in COPD. Pulmonary rehabilitation increases 6MWD by approximately 50m on average.

Online Medical Tools — BODE Index

BODE Index

How It Works

Measure and score all 4 BODE components

Sum the 4 component scores (total 0–10)

Interpret the BODE quartile for prognosis and referral decisions

Who Uses the BODE Index

COPD Mortality Risk Communication

Lung Transplant Referral Threshold (BODE ≥5)

Pulmonary Rehabilitation Outcome Tracking (Serial BODE)

Lung Volume Reduction Surgery (LVRS) Candidate Selection

Advanced Care Planning in Severe COPD

Pro Tips

BODE captures multisystem COPD impact that FEV1 misses

6-minute walk test must follow ATS standardized protocol

BODE ≥5 triggers lung transplant referral evaluation

Low BMI in COPD signals cachexia and worsens prognosis

Pulmonary rehabilitation reduces BODE by 1–2 points

Use post-bronchodilator FEV1 for BODE calculation

BODE should be performed at stable baseline, not during exacerbation

Monitor BODE annually in GOLD 3–4 patients

BODE improvement after LVRS in select upper-lobe patients

Declining BODE >1 point per year signals accelerating disease

Common Questions About Your Results

Evidence-Based Methodology

Clinical Content Trust

How to Interpret Your Result

When to Use This Tool

Limitations

Changelog

Related Tools

COPD GOLD

mMRC Dyspnea Scale

Pack-Year Calculator

ACT Score

Further Reading

A Comprehensive Guide to Pulmonology: Respiratory Assessment Tools and Lung Health

Frequently Asked Questions